Stay updated with breaking news from Libretto 531. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Selpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients with advanced, multikinase inhibitor–naïve, RET-mutant medullary thyroid cancer, according to interim findings from the phase 3 LIBRETTO-531 trial. ....